All In Biotech

Drug Trial Radar · NCT03850795

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

104

Actual

Start

Mar 15, 2021

Primary completion

Jun 28, 2024

Study completion Jun 28, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multinational Phase 3, randomized, double-blind, non-inferiority, efficacy and safety study of oral HC-1119 (80 mg/day) versus enzalutamide (160 mg/day) in asymptomatic or mildly symptomatic patients with progressive metastatic castration-resistant prostate cancer (mCRPC). The following assessment of prostate cancer status will be collected during the course of the trial: soft tissue disease on computed tomography (CT) scan or on magnetic resonance imaging (MRI), bone disease on radionuclide bone scans, FACT-P and EQ-5D, Brief Fatigue Inventory, and PSA. Throughout the study, safety and tolerability will be assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Blood samples for population pharmacokinetics for HC-1119 and enzalutamide and related metabolites will be collected.

Conditions

  • Prostate Cancer Metastatic
  • Castration-resistant Prostate Cancer

Interventions

  • HC-1119Drug

    oral once daily 80 mg

  • EnzalutamideDrug

    oral once daily 160 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Week 24

Locations

58 sites in 14 countries. Site status is shown where the registry gives one.

  • Urology Center of Colorado, 2777 Mile High Stadium Circle

    Denver, Colorado

  • Urologic Surgeons of Washington

    Washington D.C., District of Columbia

  • First Urology PSC, 101 Hospital Boulevard

    Jeffersonville, Indiana

  • Clinical Research Solutions PC

    Middleburg Heights, Ohio

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania

  • Keystone Urology Specialists

    Lancaster, Pennsylvania

  • Urology San Antonio Stone Oak, 18915 Meisner Drive

    San Antonio, Texas

  • Providence Regional Cancer System

    Lacey, Washington

  • Affinity Clinical Research

    Nedlands, Australia

  • Icon Cancer Care Gold Coast

    Southport, Queensland, Australia

  • Ashford Cancer Centre Research

    Kurralta Park, South Australia, Australia

  • Kepler Universitätsklinikum Linz

    Linz, Austria

  • Fe/Male Health Centre

    Oakville, Ontario, Canada

  • CIUSSS de l'Estrie-CHUS

    Sherbrooke, Quebec, Canada

  • Aalborg Universitetshospital

    Aalborg, Denmark

  • Odense Universitetshospital

    Odense C, Denmark

  • Helsinki University Hospital Comprehensive Cancer Center - PPDS

    Helsinki, Finland

  • Oulun Yliopistollinen Sairaala

    Oulu, Finland

  • Seinäjoen Keskussairaala

    Seinäjoki, Finland

  • Tampereen yliopistollinen sairaala

    Tampere, Finland

  • Centre Jean Bernard Clinique Victor Hugo

    Le Mans, France

  • CHRU Lille

    Lille, France

  • Centre Léon Berard

    Lyon, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Hopital d'Instruction des Armées de Begin

    Saint-Mandé, France

  • Hopital Foch

    Suresnes, Hauts-de-Seine, France

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • UroGynZentrum Wall

    Wuppertal, Germany

  • Urologische Studienpraxis

    Nürtingen, Baden-Wurttemberg, Germany

  • Azienda Ospedaliera Universitaria Integrata Di Verona

    Verona, Italy

  • Azienda Ospedaliera S Maria Di Terni

    Terni, Umbria, Italy

  • Canisius Wilhelmina Ziekenhuis

    Nijmegen, Gelderland, Netherlands

  • Catharina Hospital

    Eindhoven, North Brabant, Netherlands

  • Antonius Ziekenhuis

    Sneek, Provincie Friesland, Netherlands

  • Hagaziekenhuis

    The Hague, South Holland, Netherlands

  • Onko-Centrum Sp. z o.o.

    Lublin, Poland

  • Urologica Praktyka Lekarska Adam Marcheluk

    Siedlce, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy

    Warsaw, Poland

  • Clinical Research Center Spolka z Ograniczona

    Poznan, Greater Poland Voivodeship, Poland

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.